Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03240016
Title Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

transitional cell carcinoma

Therapies

Nab-paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.